Proactive Investors - Run By Investors For Investors

RedHill BioPharma lead drug making its way towards FDA approval

RedHill Biopharma (NASDAQ:RDHL) CEO Dror Ben-Asher sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biopharmaceutical company is primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases.

 
View full RDHL profile View Profile

RedHill Biopharma Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use